Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2009

View Archived Issues

New HCV RNA-dependent RNA polymerase NS5B inhibitors developed at GSK

Bayer reports novel prostacyclin PGI2 receptor agonists

Dual-action inhibitors of Tie2 and KDR kinase prepared and tested at Bayer Schering Pharma

Novel SSTR5 antagonists with antidiabetic properties developed at Roche

AstraZeneca claims new chemokine CCR1 receptor ligands as antiasthmatic agents

Trius completes enrollment in phase II torezolid trial in cSSSI

Rib-X announces positive phase II study results for delafloxacin in cSSSI

Halozyme presents positive preclinical data for PEGPH-20

Rexahn completes patient enrollment in phase IIa clinical trial of Zoraxel for ED

MAP completes patient enrollment in phase III clinical trial of MAP-0004

ImClone and Bristol-Myers Squibb withdraw and are to resubmit sBLA for Erbitux

Plerixafor mobilizes different progenitor cell subsets when given with G-CSF or VEGF

Antitope and Opsona generate new therapeutic antibody Opn-305

Levosimendan a potential treatment for chronic obstructive pulmonary disease

Tripep initiates phase II study in Norway and Sweden of ChronSeal for chronic leg wounds

Onconova successfully completes first dose cohort of phase I clinical trial of Ex-RAD

BioInvent and ThromboGenics receive technology transfer success fee for TB-403

Crucell and Wyeth discontinue discussions on possible combination

Debiopharm randomizes first patient in phase IIb Debio-025 hepatitis C trial

Pfizer to acquire Wyeth under definitive merger agreement

KV receives notice of delayed NDA approval for Gestiva

Basilea focuses on commercialization of its products and high priority programs

CTI to begin rolling NDA submission for pixantrone for non-Hodgkin's lymphoma

FDA accepts Sirion's ganciclovir NDA for review for treatment of ocular herpes

Seattle Genetics receives FDA and EMEA orphan drug designations for SGN-35